CN  /  EN

imgboxbg

NEWS

最新消息

“绝味”商标维权 [ 2022-01-14 ]
绝味食品股份有限公司,是“绝味鸭脖”母公司,成立于2005年,其名下“绝味”商标在2009年注册于29类食品上,于2010年被商标局认定为驰名商标。
Disney is an American multinational entertainment and media conglomerate headquartered in the U.S. The company established itself as a leader in the American animation industry before diversifying into live-action film production, television, and theme parks. Furthermore, Disney is famous for pushing the envelope regarding theme park technologies.
为了促使刑事涉案企业依法合规经营,做实“少捕慎诉慎押”刑事司法政策,同时警示潜在的违法违规企业守法经营,最高人民检察院从2020年3月起稳步推进企业合规改革试点。
上一期推送中我们提到,原告被告都是外企,他们却纷纷选择来到中国提起专利诉讼(点击蓝字回顾原文),从中可以了解到:中国已成为世界上专利诉讼的主战场。那么,这些外企来自哪些国家呢? 从发明专利案件数量来看,过去十年间,以日本企业提起的发明专利案件数量最多,德国位居第二,美国排名第三。其中,戴森(Dyson Technology)的诉讼官司大幅提升了英国的排名,37件发明专利案件中占了28件。 日本公司为原告的数量排名第一其实并不意外。日本的地理位置上很靠近中国,这使日本企业更了解中国市场,且很可能产生利益竞争关系。这些因素大大增加了这些企业在中国提出诉讼的可能。 然而令人惊讶的是,同样是邻居的韩国企业提出的诉讼数量极低,在专利战略上远不及日本积极。一个可能的解释是,日本企业长期以来一直是中国地区专利的积极申请者,这意味着他们已经积累了大量适合提起诉讼的组合。另一方面,韩国企业可能在此年代没有布局中国,因此没有那么多的专利可以出击,故而出现了这样的极其明显的对比。
Established in 2018, Ruige Pharmaceutical is committed to the fields of tumors, autoimmunity and metabolism, and develops "first-in-class" and "best-in-class" innovative drugs with independent intellectual property rights. Recently, Ruige Pharmaceutical announced that its new generation of CDK2/4/6 small- molecule inhibitor RGT-419B has been received FDA approval for clinical research. RGT-419B is a new-generation tumor-targeted inhibitor with an optimized kinase activity spectrum. It is expected to improve the safety of currently approved CDK4/6 inhibitors and overcome resistance to these inhibitors. These inhibitors are used in combination with endocrine therapy to treat patients with premenopausal/postmenopausal hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer. In cell model experiments, RGT-419B showed single-drug activity, which has a greater inhibitory effect on the growth of estrogen receptor positive (ER+) tumor cells. In ER+ breast cancer cells resistant to currently approved CDK4/6 inhibitors, RGT-419B showed complete inhibition of cancer cell proliferation. In these experiments, when RGT-419B is used in combination with a selective estrogen receptor degrader or PI3K signaling pathway inhibitor, its inhibitory effect on tumor cells is further enhanced. As a single agent and used in combination with other approved therapies, RGT-419B will initially be developed for the treatment of human epidermal growth factor receptor 2 negative (HER2-), ER+ breast cancer patients who have primary or acquired resistance to CDK4/6 inhibitors. With the widespread adoption of CDK4/6 inhibitors in clinical practice, patients with refractory and relapsed patients are becoming larger and clinically significant unmet medical needs. The clinical development project of RGT-419B will solve this resistance to CDK4/6 and other hormone receptor modulating therapies, and provide new opportunities for improving the survival and quality of life of patients with advanced breast cancer. RGT-419B is the first of many innovative oncology drugs being developed by Ruige Pharmaceutical. Founder and CEO Dr. Qiu Xiayang said: "This milestone marks the successful entry of Ruige Pharmaceutical into the field of tumor treatment. We have found the best choice for multiple CDKs through our self-developed AI-assisted new drug development CARD platform. Successfully promoted innovative drugs to enter the clinical development stage in the United States. At the same time, we are very excited that this opportunity can bring new and differentiated treatment options to many breast cancer patients around the world.
此次大会全称为台湾国际半导体展(SEMICON Taiwan 2021)由国际半导体产业协会(SEMI)主办。
华讯一直行走在软件信息的专利顾问服务前沿,紧跟软件信息产业发展的脚步,致力于为企业提供最专业的知识产权服务,为中国软件信息产业的发展出一份力。
这是一个有趣的趋势:由于种种原因,国外企业纷纷选择在中国提起专利诉讼,起诉非中国企业。
本次活动截稿时间为2022年1月15日,稿件请投递至邮箱:wenqian.li@chinaipic.com,投递时请在邮件主题标明:学校+姓名+联系方式。 活动从即日起开始,欢迎大家踊跃报名参加!
上一页
1
2
...
59
这是描述信息

江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

版权所有◎南京华讯知识产权顾问有限公司

备案号:苏ICP备xxxxxx号-1    网站建设:中企动力 南京